Lung Cancer | Specialty

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

NCCN Guidelines Recommend Lurbinectedin as Second-Line Treatment in Relapsed SCLC

July 15th 2020

Lurbinectedin was added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network on July 7, 2020 for the treatment of patients with small cell lung cancer.

Pepinemab/Avelumab Combo Shows Early Tolerability and Antitumor Activity in Advanced NSCLC

July 15th 2020

The combination of pepinemab and avelumab was found to be well tolerated and demonstrated initial signals of antitumor activity in patients with advanced stage, non–small cell lung cancer.

New Indication Propels Brigatinib Into the Front Line for ALK-Positive NSCLC

July 15th 2020

Thomas E. Stinchcombe, MD, discusses brigatinib’s mechanism as well as the next steps to advance the treatment paradigm for patients with ALK-positive NSCLC.

Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC

July 13th 2020

Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.

Multidisciplinary Management of Patients With Stage III NSCLC

July 13th 2020

Integrating Perioperative Immunotherapy Strategies in NSCLC

July 13th 2020

Molecular testing in Patients With Metastatic NSCLC

July 13th 2020

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

July 13th 2020

Varied Timing of IO Therapy in Patients With Stage III NSCLC

July 13th 2020

Treating for Stage III NSCLC After Progression on Durvalumab

July 13th 2020

Durvalumab in Stage III NSCLC Based on Performance Status

July 13th 2020

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

July 13th 2020

Mediastinal Staging in Non–Small Cell Lung Cancer

July 13th 2020

Dr. Pennell on Challenges With NGS in Lung Cancer

July 10th 2020

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

SHAWL Study: A Sexual Health Assessment in Women With Lung Cancer

July 10th 2020

Data suggest that up to 95% of patients with lung cancer score below the fiftieth percentile on sexual function during and after completion of cancer-directed therapy.

Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

July 9th 2020

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Investigators Leverage Radiomics to Risk Stratify Patients With Early-Stage Lung Cancer

July 9th 2020

Matthew Schabath, PhD, discusses the use of peritumoral and intratumoral radiomic features, where investigators created a model that identified patients with early-stage lung cancer at high risk of experiencing poor survival outcomes.

Trastuzumab Deruxtecan Shakes Up HER2-Mutated NSCLC Treatment Paradigm

July 7th 2020

Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting lung cancer data.

Roswell Park Is First Center in New York State to Implement Monarch Bronchoscopy Platform

July 7th 2020

Minimally invasive tool uses robotic technology to enable earlier, more accurate diagnosis of lung nodules.